GCP
PCRX icon

GSA Capital Partners’s Pacira BioSciences PCRX Stock Holding History

GSA Capital Partners’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,973
Closed -$273K – 2053
2025
Q1 		$273K Buy
+10,973
New +$263K 0.02% 1217
2024
Q2 		– Sell
-22,722
Closed -$664K – 1938
2024
Q1 		$664K Sell
22,722
-2,030
-8% -$62.4K 0.05% 711
2023
Q4 		$835K Buy
+24,752
New +$724K 0.07% 487
2023
Q2 		– Sell
-22,384
Closed -$913K – 1840
2023
Q1 		$913K Sell
22,384
-11,835
-35% -$471K 0.09% 363
2022
Q4 		$1.32M Buy
+34,219
New +$1.66M 0.16% 93
2020
Q2 		– Sell
-21,875
Closed -$733K – 988
2020
Q1 		$733K Buy
+21,875
New +$909K 0.18% 44
2019
Q4 		– Sell
-16,592
Closed -$632K – 1655
2019
Q3 		$632K Sell
16,592
-19,451
-54% -$776K 0.09% 406
2019
Q2 		$1.57M Buy
+36,043
New +$1.53M 0.18% 83
2019
Q1 		– Sell
-7,400
Closed -$318K – 1627
2018
Q4 		$318K Buy
+7,400
New +$345K 0.04% 809
2016
Q3 		– Sell
-29,900
Closed -$1.01M – 1912
2016
Q2 		$1.01M Buy
29,900
+19,800
+196% +$973K 0.06% 620
2016
Q1 		$535K Buy
+10,100
New +$591K 0.03% 973
2015
Q3 		– Sell
-18,550
Closed -$1.31M – 1966
2015
Q2 		$1.31M Sell
18,550
-8,700
-32% -$685K 0.05% 679
2015
Q1 		$2.42M Buy
27,250
+17,700
+185% +$1.8M 0.1% 242
2014
Q4 		$847K Sell
9,550
-3,821
-29% -$361K 0.06% 575
2014
Q3 		$1.3M Buy
+13,371
New +$1.3M 0.07% 356
2014
Q2 		– Sell
-32,197
Closed -$2.25M – 1925
2014
Q1 		$2.25M Buy
32,197
+16,392
+104% +$1.11M 0.16% 121
2013
Q4 		$909K Buy
15,805
+9,251
+141% +$486K 0.07% 428
2013
Q3 		$315K Sell
6,554
-11,983
-65% -$437K 0.02% 1114
2013
Q2 		$538K Buy
+18,537
New +$536K 0.06% 503

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

GSA Capital Partners's PCRX Position: Q2 2025 in Review

GSA Capital Partners sold out of Pacira BioSciences (PCRX) in Q2 2025, closing a stake of 10,973 shares — an estimated $273K sold.

GSA Capital Partners first reported a position in PCRX in Q2 2013 and held it in 19 quarters. The position peaked at $2.42M in Q1 2015. 233 funds tracked by Wall St. Rank hold PCRX as of Q2 2025.

  • GSA Capital Partners reported no remaining Pacira BioSciences position as of Q2 2025 after selling out during the quarter.
  • GSA Capital Partners sold 10,973 Pacira BioSciences shares in Q2 2025, an estimated $273K.
  • GSA Capital Partners first reported a position in Pacira BioSciences in Q2 2013 and held it in 19 quarters.
  • GSA Capital Partners's Pacira BioSciences position peaked at $2.42M in Q1 2015.
  • 233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2025.

Based on GSA Capital Partners's 13F filing for Q2 2025, filed 22 Jul 2025.